Skip to content

Released Jul 31, 2024, after the close

10-Q filed Aug 6, 2024, 37 days after period end · 0000950170-24-091888

Q2 2024 · 10-Q
Revenue$22.49M−18.7% vs Q2 2023−50.6% vs Q1 2024
Net Income-$45.72MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.12N/M vs Q2 2023N/M vs Q1 2024
Gross Profit$10,374,000−23.7%
Operating Income-$30,261,000N/M
Operating Cash Flowderived-$39,050,000N/M
Free Cash Flowderived-$40,987,000N/M
Margins · derived
Gross margin46.1%−3.0 pt vs Q2 2023
Operating margin-134.5%−71.5 pt vs Q2 2023
Net margin-203.3%−141.7 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$22.49M$27.67M$18.78M$31.02M
Net Income-$45.72M-$17.04M-$63.54M-$17.14M
EPS Diluted-$0.12-$0.22-$0.82-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR